RxDoctor Payments Data

Jason Warczinsky

Family · Flint, MINPI 1053904805

Payments from drug & device makers

$5,341in general payments, 2019–2025

Across 142 payments — averaging $37.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$2K
  • Merck$345
  • Coloplast$311
  • Sumitomo Pharma America, Inc.$302
  • Astellas Pharma US Inc$291
  • Dendreon Pharmaceuticals LLC$249
  • plus $1K from 23 others

What the payments were for

  • Travel & lodging$1,81234%
  • Food & beverage$3,34563%
  • Education$1853%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,341 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron41$43,965
MyrbetriqMirabegron29$28,292
Mirabegron ErMirabegron25$14,287
Tamsulosin Hcl425$9,314
Testosterone47$5,260
Methenamine Hippurate42$4,294
Trospium Chloride ErTrospium Chloride17$2,960
Finasteride138$2,838
Oxybutynin Chloride ErOxybutynin Chloride124$2,572
Trospium Chloride24$1,491
Trimethoprim13$1,065
Tolterodine Tartrate ErTolterodine Tartrate19$882
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst46$692
Cephalexin47$679
NitrofurantoinNitrofurantoin Macrocrystal12$593

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$302$43,96541 claims
Astellas Pharma US IncMyrbetriq$291$28,29229 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.

Other family in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →